Sarepta obtains exclusive worldwide licenses to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including potential best-in-class siRNA-based treatments for DM1 and FSHD
– Additionally, Arrowhead and Sarepta have entered into a discovery partnership pursuant to which Sarepta will nominate, and Arrowhead will deliver, IND-ready constructs for six targets across skeletal muscle, cardiac, and CNS
– Investigational treatments leverage Arrowhead’s leading Targeted RNAi Molecule (TRiMTM) platform, capable of deep and durable target-gene knockdown
– Upon closing, Arrowhead to receive $500 million in an upfront payment and $325 million equity investment at a 35% premium, plus additional future milestone payments and royalties
– Separately, Sarepta’s Board of Directors has approved a share repurchase authorization of up to $500 million
– Sarepta to host an investor conference call on Tuesday, Nov. 26, 2024, at 8:30 a.m. ET
At 8:30 a.m. ET on Nov. 26, 2024, Sarepta will host a conference call and webcast to discuss this agreement.
The event will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.